Acurx Pharmaceuticals reported total assets of $10.98M and total liabilities of $2.83M for the quarter ended Jun 2026, up 78.4% year over year. This balance sheet covers 24 quarters of results from Sep 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Balance Sheet | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||||||
| Current Assets | ||||||||||||||||||||||||
| Cash & EquivalentsCash & Equiv. | 14.46M | 12.96M | 11.08M | 9.09M | 10.61M | 9.11M | 7.18M | 9.15M | 7.05M | 7.47M | 8.92M | 6.36M | 5.76M | 3.71M | 4.64M | 6.06M | 5.91M | 7.56M | 9.30M | 10.70M | ||||
| Receivables - NetNet Receivables | 0.13M | 0.05M | 0.10M | 0.05M | 0.04M | 0.04M | 0.05M | 0.06M | 0.10M | |||||||||||||||
| Receivables - OtherOther Receivables | 0.04M | |||||||||||||||||||||||
| Receivables | 0.13M | 0.05M | 0.10M | 0.05M | 0.04M | 0.04M | 0.05M | 0.06M | 0.14M | |||||||||||||||
| Prepaid Assets | 0.53M | 0.30M | 0.24M | 0.12M | 0.34M | 0.26M | 0.21M | 0.09M | 0.11M | 0.11M | 0.19M | 0.17M | 0.12M | 0.10M | 0.16M | 0.05M | 0.16M | 0.09M | 0.23M | 0.23M | ||||
| Current Assets | 13.25M | 9.21M | 10.95M | 9.38M | 7.39M | 9.24M | 7.16M | 7.71M | 5.98M | 3.86M | 4.81M | 6.16M | ||||||||||||
| Non-Current Assets | ||||||||||||||||||||||||
| Other Non-Current Assets | 0.05M | |||||||||||||||||||||||
| Non-Current Assets | 0.05M | |||||||||||||||||||||||
| Assets | 14.99M | 13.25M | 11.32M | 9.26M | 10.95M | 9.38M | 7.39M | 9.24M | 7.16M | 7.71M | 9.11M | 6.58M | 5.98M | 3.86M | 4.81M | 6.16M | 6.11M | 7.69M | 9.54M | 10.98M | ||||
| Liabilities | ||||||||||||||||||||||||
| Current Liabilities | ||||||||||||||||||||||||
| Accounts Payables | 0.71M | 0.84M | 0.63M | 0.47M | 1.18M | 2.06M | 2.07M | 3.02M | 3.22M | 3.04M | 3.11M | 3.15M | 3.32M | 3.24M | 2.49M | 2.59M | 2.47M | 2.42M | 2.53M | 2.83M | ||||
| Payables | 0.71M | 0.84M | 0.63M | 0.47M | 1.18M | 2.06M | 2.07M | 3.02M | 3.22M | 3.04M | 3.11M | 3.15M | 3.32M | 3.24M | 2.49M | 2.59M | 2.47M | 2.42M | 2.53M | 2.83M | ||||
| Accumulated Expenses | 0.31M | 0.51M | 0.53M | 0.30M | 0.76M | 1.41M | 1.91M | 2.88M | 2.97M | 2.26M | 2.76M | 2.98M | 2.97M | 2.66M | 2.26M | 2.38M | 2.35M | 2.31M | 2.38M | 2.77M | ||||
| Total Current Liabilities | 0.71M | 0.84M | 0.63M | 0.47M | 1.18M | 2.06M | 2.07M | 3.02M | 3.22M | 3.04M | 3.11M | 3.15M | 3.32M | 3.24M | 2.49M | 2.59M | 2.47M | 2.42M | 2.53M | 2.83M | ||||
| Non-Current Liabilities | ||||||||||||||||||||||||
| Other Non-Current Liabilities | 0.62M | 0.62M | 0.62M | |||||||||||||||||||||
| Total Non-Current Liabilities | 0.23M | 0.02M | -0.14M | |||||||||||||||||||||
| Total Liabilities | 0.71M | 0.84M | 0.63M | 0.47M | 1.18M | 2.06M | 2.07M | 3.02M | 3.22M | 3.04M | 3.11M | 3.15M | 3.32M | 3.24M | 2.49M | 2.59M | 2.47M | 2.42M | 2.53M | 2.83M | ||||
| Shareholder's Equity | ||||||||||||||||||||||||
| Common Equity | 14.28M | 12.41M | 10.69M | 8.79M | 9.76M | 7.32M | 5.31M | 6.22M | 3.93M | 4.67M | 6.00M | 3.43M | 2.66M | 0.62M | 2.31M | 3.57M | 3.64M | 5.27M | 7.01M | 8.15M | ||||
| Liabilities and Shareholders Equity | 14.99M | 13.25M | 11.32M | 9.26M | 10.95M | 9.38M | 7.39M | 9.24M | 7.16M | 7.71M | 9.11M | 6.58M | 5.98M | 3.86M | 4.81M | 6.16M | 6.11M | 7.69M | 9.54M | 10.98M | ||||
| Retained Earnings | 38.19M | 38.95M | 39.90M | 40.61M | 45.13M | 45.94M | 46.84M | 51.19M | 52.03M | 57.87M | 63.58M | 65.13M | 67.19M | 67.94M | 71.76M | 75.28M | 77.35M | 80.55M | 83.98M | 87.37M |